奥沙利铂联合卡培他滨(希罗达)治疗晚期胃癌临床研究  

Oxaliplatin plus Xeloda for Advanced Carcinoma of Stomach:A Clinical Research

作　　者：庄莉[1] 毕清[1] 任宏轩[1] 杨冠勤[1] 

机构地区：[1]云南省肿瘤医院内科化疗中心二病区,昆明市650118

出　　处：《中国医院用药评价与分析》2009年第2期147-148,共2页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:观察奥沙利铂联合卡培他滨(希罗达)治疗晚期胃癌的近期疗效及不良反应。方法:38例确诊为晚期胃癌的患者,第1天奥沙利铂130mg.(m2)-1静脉滴注2h;第1～14天,口服卡培他滨2000mg.(m2)-1,分2次服用,d1～14,每3周为1周期。38例患者均接受化疗2～4周期治疗后评价疗效。结果:CR5例(13.16%),PR15例(39.47%),SD10例(26.32%),PD8例(21.05%),总有效率为52.63%,中位生存期9.0个月。出现不良反应症状主要为Ⅱ～Ⅲ度,可耐受。结论:奥沙利铂联合卡培他滨治疗晚期胃癌疗效较好,不良反应可耐受。OBJECTIVE： To study the short - term efficacy and toxicity of Oxaliplatin plus Capecitabine for advanced carcinoma of stomach. METHODS ： A total of 38 patients who had been confirmed as having advanced carcinoma of stomach were assigned to receive Oxaliplatin [ 130 mg·（m2）^ -1, iv gtt for 2 hi on day 1 in combination with Capecitabine [2 000 mg·（m2）^ -1 in two divided doses] from day I to day 14, with 3 weeks defined as i course. The curative efficacy of the 38 cases were evaluated after receiving chemotherapy for 2 - 4 cycles. RESULTS： CR was achieved in 5 cases （13.16%）, PR in 15 （39.47%）, SD in 10 （26.32%） and PD in 8 （21.05%）; the total response rate was 52.63% and the median survival time was 9.0 months. The Ⅱ～Ⅲ degree symptoms were the chief clinical manifestation of the adverse drug reactions and which were proved to be tolerable in patients. CONCLUSION： The combination of Oxaliplatin plus Capecitabine was proved to be with good efficacy and good tolerance in patients with advanced carcinoma of stomach.

关 键 词：奥沙利铂 卡培他滨 晚期胃癌 

分 类 号：R979.1[医药卫生—药品]